Clinical Trial Update: A Survey of Recombinant ADAMTS13 in Participants With Congenital Thrombotic Thrombocytopenic Purpura

View source ↗

Summary

A clinical trial investigating recombinant ADAMTS13 in participants with congenital thrombotic thrombocytopenic purpura is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thrombotic Thrombocytopenic Purpura

Drugs mentioned

• Recombinant ADAMTS13 (ADAMTS13)

Snippet

Sponsor: Takeda | Conditions: Thrombotic Thrombocytopenic Purpura (TTP) | Status: RECRUITING